Patents Assigned to Phase 2 Discovery, Inc.
  • Publication number: 20040142962
    Abstract: The present invention describes a method for the treatment of attention deficit hyperactivity disorder (ADHD), conduct disorder, alcohol addiction, tobacco addiction, nicotine addiction, parkinsonism including Parkinson's disease, female and male orgasmic disorders, female and male sexual arousal disorders, hypoactive sexual desire disorder, and disorders characterized by anxiety and/or depression. In this method, a therapeutically effective, nontoxic dose of a 4′,4″-substituted 3&agr;-(diphenylmethoxy) tropane analog or a pharmaceutically acceptable salt thereof is administered to the patient in need of such treatment.
    Type: Application
    Filed: January 7, 2004
    Publication date: July 22, 2004
    Applicant: Phase 2 Discovery, Inc.
    Inventor: Frank P. Zemlan
  • Patent number: 6482440
    Abstract: Pharmaceutically-active materials comprising specific antidepressant compounds, such as sertraline, contained in microparticles formulated so as to release the antidepressant compounds over an extended period of time are disclosed. The materials, when administered, particularly by injection, release the active agent over time allowing the patient to be effectively treated without requiring multiple dosing of the pharmaceutical material. Pharmaceutical compositions containing the microparticles and methods of treating depression-related conditions utilizing the microparticles are also disclosed.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: November 19, 2002
    Assignee: Phase 2 Discovery, Inc.
    Inventors: Frank P. Zemlan, Jeffrey Mulchahey
  • Publication number: 20020132854
    Abstract: Pharmaceutically-active materials comprising specific antidepressant compounds, such as sertraline, contained in microparticles formulated so as to release the antidepressant compounds over an extended period of time are disclosed. The materials, when administered, particularly by injection, release the active agent over time allowing the patient to be effectively treated without requiring multiple dosing of the pharmaceutical material. Pharmaceutical compositions containing the microparticles and methods of treating depression-related conditions utilizing the microparticles are also disclosed.
    Type: Application
    Filed: August 30, 2001
    Publication date: September 19, 2002
    Applicant: Phase 2 Discovery, Inc.
    Inventors: Frank P. Zemlan, Jeffrey Mulchahey